Stereotactic radiosurgery for XXXX : preliminary report of a phase I trial.

@entity1 @entity1313 @entity5 @entity2 @entity2415 @entity3
BACKGROUND: Stereotactic radiosurgery is well established for the treatment of @entity1313 but its use for @entity2 is novel. METHODS: Twenty-three @entity1 with biopsy-proven @entity2 were recruited into a two-institution, dose-escalation, phase I clinical trial using a frameless stereotactic radiosurgery system (CyberKnife). Fifteen @entity1 had primary @entity2 and 8 had @entity3 . The age range was 23 to 87 years (mean, 63 years). After undergoing computed tomography-guided percutaneous placement of two to four small metal fiducials directly into the @entity5 , @entity1 received 1,500 cGY of radiation in a single fraction using a linear accelerator mounted on a computer-controlled robotic arm. Safety, feasibility, and efficacy were studied. RESULTS: Nine @entity1 were treated with a breath-holding technique, and 14 with a respiratory-gating, automated, robotic technique. @entity5 size ranged from 1 to 5 cm in maximal diameter. There were four complications related to fiducial placement: three pneumothoraces requiring chest tube insertion and one @entity2415 exacerbation. There were no grade 3 to 5 radiation-related complications. Follow-up ranged from 1 to 26 months (mean, 7.0 months). Radiographic response was scored as complete in 2 @entity1 , partial in 15, stable in 4, and progressive in 2. Four @entity1 died of non-treatment-related causes at 1, 5, 9, and 11 months after radiation. CONCLUSIONS: Single-fraction stereotactic radiosurgery is safe and feasible for the treatment of selected @entity2 . Additional studies are planned to investigate the optimal radiation dose, best motion-suppression technique, and overall treatment efficacy.
